We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
+16.35%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$239M
AUM Growth
-$103M
(-30%)
Cap. Flow
-$106M
Cap. Flow
% of AUM
-44.2%
Top 10 Holdings %
Top 10 Hldgs %
35.32%
Holding
114
New
39
Increased
6
Reduced
19
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$3.8M |
| 2 |
HCA Healthcare
HCA
|
+$3.62M |
| 3 |
HOLX
Hologic
HOLX
|
+$3.59M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$3.47M |
| 5 |
Medtronic
MDT
|
+$3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$9.9M |
| 2 |
Centene
CNC
|
+$7.74M |
| 3 |
AGN
Allergan plc
AGN
|
+$7.17M |
| 4 |
DexCom
DXCM
|
+$6.24M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$6.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.43% |
| 2 | Industrials | 2.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
76
Centene
CNC
$32.8B
| – | – |
-160,000
| Closed | -$7.74M |
|
77
Collegium Pharmaceutical
COLL
$888M
| – | – |
-117,131
| Closed | -$1.23M |
|
|
78
CALL
DexCom
DXCM
$33.1B
| – | – |
-220,000
| Closed | -$2.69M |
|
|
79
DexCom
DXCM
$33.1B
| – | – |
-480,000
| Closed | -$6.24M |
|
80
CALL
Edwards Lifesciences
EW
$53.2B
| – | – |
-105,000
| Closed | -$3.83M |
|
81
CALL
Exelixis
EXEL
$13.1B
| – | – |
-50,600
| Closed | -$1.23M |
|
|
FOLD
82
CALL
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-200,000
| Closed | -$3.02M |
|
83
Incyte
INCY
$24.7B
| – | – |
-50,000
| Closed | -$5.23M |
|
84
Indaptus Therapeutics
INDP
$155M
| – | – |
-45
| Closed | -$895K |
|
85
Insmed
INSM
$29B
| – | – |
-87,601
| Closed | -$2.73M |
|
|
LITS
86
CALL
Lite Strategy Inc
LITS
$29.4M
| – | – |
-9,825
| Closed | -$527K |
|
87
Molina Healthcare
MOH
$10.3B
| – | – |
-25,000
| Closed | -$1.72M |
|
|
88
Merck
MRK
$323B
| – | – |
-161,989
| Closed | -$9.9M |
|
89
CALL
Puma Biotechnology
PBYI
$449M
| – | – |
-25,000
| Closed | -$2.99M |
|
90
CALL
Pfizer
PFE
$154B
| – | – |
-527,000
| Closed | -$17.9M |
|
91
CALL
PTC Therapeutics
PTCT
$6.15B
| – | – |
-102,800
| Closed | -$2.06M |
|
92
QuidelOrtho
QDEL
$907M
| – | – |
-110,000
| Closed | -$4.83M |
|
|
93
PUT
QuidelOrtho
QDEL
$907M
| – | – |
-28,000
| Closed | -$1.23M |
|
94
CALL
Qiagen
QGEN
$9.06B
| – | – |
-75,444
| Closed | -$2.52M |
|
95
Regenxbio
RGNX
$689M
| – | – |
-33,920
| Closed | -$1.12M |
|
96
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$809B
| – | – |
-100,000
| Closed | -$25.1M |
|
97
Sarepta Therapeutics
SRPT
$1.78B
| – | – |
-50,000
| Closed | -$2.27M |
|
98
Savara
SVRA
$1.16B
| – | – |
-173,023
| Closed | -$1.62M |
|
99
Vertex Pharmaceuticals
VRTX
$133B
| – | – |
-29,900
| Closed | -$4.55M |
|
|
RVNC
100
DELISTED
Revance Therapeutics, Inc.
RVNC
| – | – |
-50,000
| Closed | -$1.38M |
|
Similar funds
BCA
RC
DOFI
SR
SCI
LPC
GBCP
SCTC
Pura Vida Investments's Q4 2017 Portfolio in Review
As of Q4 2017, Pura Vida Investments held 114 positions worth $239M, down 30% from $342M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Pura Vida Investments withdrew a net $106M in Q4 2017, closing 45 positions and reducing 19 holdings. Its most notable exit was Merck, an estimated $9.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 50% a quarter earlier, followed by Industrials.
Against the trend, Pura Vida Investments opened a new position in BioMarin Pharmaceuticals worth $3.9M.
- Pura Vida Investments's largest Q4 2017 buy was BioMarin Pharmaceuticals: 43,700 shares worth $3.9M.
- Pura Vida Investments added most to Zogenix, Inc. in Q4 2017, an estimated $3.47M increase.
- Pura Vida Investments's biggest Q4 2017 reduction was LivaNova, cutting an estimated $5.1M.
- Pura Vida Investments fully exited Merck in Q4 2017, selling an estimated $9.9M.
- Pura Vida Investments's ten largest holdings make up 35% of its $239M portfolio in Q4 2017.
- Pura Vida Investments opened 39 new positions and closed 45 in Q4 2017.
- Pura Vida Investments's portfolio value fell 30% quarter-over-quarter to $239M.
Based on Pura Vida Investments's 13F filing for Q4 2017, filed 14 Feb 2018.